Document:

EX-10.1

 

EXHIBIT 10.1

March 14, 2007

Jeffrey L. Radke

c/o PXRE Group Ltd.

PXRE House

110 Pitts Bay Road

Hamilton, HM 08 Bermuda

			
	     Re:	 	Separation Letter Agreement (this “Letter Agreement”)

Dear Jeff:

Your last day of employment with and service as a Director of PXRE Group Ltd. (the “Company”), and
each of the Company’s direct and indirect subsidiaries, including, without limitation, PXRE
Corporation, PXRE Reinsurance Company and PXRE Reinsurance Ltd. (collectively with the Company,
“PXRE”) will be the earliest of (i) December 28, 2007, (ii) the date of the closing under the
Agreement and Plan of Merger by and among the Company, PXMS, Inc. and Argonaut Group, Inc. dated as
of March 14, 2007, or, in the event that a closing does not occur as aforesaid for any reason, the
date of the closing of an alternative transaction in which the Company is acquired (whether by
merger or in a sale of assets or capital stock) by an unaffiliated person or entity, (iii) the date
you terminate your employment by written notice to the Company for “Good Reason” (as defined in
paragraph 17 below) under this Letter Agreement or (iv) the date your employment with the Company
is terminated by written notice to you other than for “Cause” (as defined in paragraph 17 below)
under this Letter

1

 

Agreement (the “Separation Date”). We and you hereby agree that your termination on the Separation
Date constitutes termination without Cause for purposes of all of the Company’s compensation,
equity and benefit plans and programs, except for the Company’s 2004 Incentive Bonus Compensation
Plan, your entitlements under which are governed by Section 1(e) hereof.

     Subject to your acceptance of this Letter Agreement in the manner described in Section 21
below, and provided that you do not terminate your employment prior to the Separation Date other
than on account of Good Reason and provided that prior to the Separation Date the Company does not
terminate your employment for Cause, you shall be entitled to, and the Company shall pay and
provide you with, the payments, compensation, benefits and entitlements in connection with your
termination of employment as follows:

	1.	 	Compensation and Benefits. In addition to your final paycheck and your vested benefits under
the Company’s Retirement Plan, 401(k) Plan and Supplemental Executive Retirement Plan,
(collectively, the “Retirement Plans”), (which vested benefits as of the Separation Date are
set forth in Exhibit A hereto and which will be paid in accordance with the terms of such
plans), you will be entitled to the following additional payments, compensation, benefits and
entitlements (subject, in each case, to applicable statutory deductions and withholdings):

	 	(a)	 	Severance Payment. You will receive a lump sum severance payment (the “Severance
Payment”) of (i) U.S. $1,626,000, plus (ii) a tax gross-up in respect of the U.S. $126,000
housing allowance payment included in the U.S. $1,626,000, which the parties agree is an
additional U.S. $61,634.46. Subject to paragraph 1(h) below, the Severance Payment shall
be paid by the Company in the form of cash on the first business day following the six
month anniversary of the Separation Date. Payments under this subsection (a) will

2

 

	 	 	 	constitute payment in full of the Base Salary and Severance Benefits payable under Sections
4.1(i), 4.6.1 and 4.6.2 of the Employment Agreement dated June 23, 2005, between the Company
and Jeffrey L. Radke (the “Employment Agreement”).
	 
	 	(b)	 	Incentive Plan. On the Separation Date, all stock options and restricted shares held
by you will fully vest, will become non-forfeitable and all restrictions thereon will
lapse. On the Separation Date, all stock options held by you will be exercisable for the
period of time provided under the applicable plan of the Company in the circumstances of a
termination of employment without cause; provided that if on or before the Separation Date
the Internal Revenue Service issues guidance, rules or regulations that counsel to the
Company and you agree permits an extension of the exercise periods of such stock options to
their original ten year periods without causing such to be a taxable event under Section
409A of the Internal Revenue Code of 1986, as amended (the “Code”), then the Company agrees
to promptly take all necessary corporate action so to extend such exercise periods.
	 
	 	(c)	 	Vacation Pay. You will receive a lump sum payment of accrued and unused vacation,
payable by the Company on the Separation Date in the form of cash. The parties hereto
agree that you will be entitled to U.S. $3,076.92 per day for each day of accrued and
unused vacation existing on the Separation Date.
	 
	 	(d)	 	Health Benefits. On the first business day following the six month anniversary of the
Separation Date, the Company will pay you for the cost of twelve (12) months of medical,
dental, disability and life insurance coverage to be obtained for you and your eligible
dependents through Colonial Medical Insurance Company Ltd. (or other similar

3

 

	 	 	 	provider) at the same coverage levels and on the same terms and conditions applicable to you
and your eligible dependents as exist immediately prior to the Separation Date, provided
that the Company shall have received appropriate documentation evidencing such cost, and
provided, further, that such reimbursement shall not exceed U.S. $30,000. Such payment
shall be in lieu of any obligation to allow continued participation by you and your eligible
dependents in any health, medical, life, disability and similar plans of the Company.
	 
	 	(e)	 	Annual Bonus. You acknowledge that no annual bonus is payable for 2006 or 2007 under
Section 2.3 of the Employment Agreement.
	 
	 	(f)	 	Other Employee Benefits. On the first business day following the six month anniversary
of the Separation Date, the Company will pay you U.S. $40,000 in cash in lieu of any
obligation to permit you to continue to participate in any compensation, deferred
compensation, 401(k), retirement and other benefit plans in which and to the extent that
you participate in such plans on the Separation Date.
	 
	 	(g)	 	Legal Fees. On the date hereof, the Company shall reimburse you for the reasonable
legal fees incurred by you in connection with the negotiation of this Letter Agreement up
to a maximum of U.S. $25,000, provided that the Company shall have received appropriate
documentation evidencing such legal fees.
	 
	 	(h)	 	Timing Rule. Notwithstanding anything in subparagraphs (a), (d) and (f) above to the
contrary, in the event that on the Separation Date, you would have had the right to any
payments pursuant to the provisions of Sections 4.6 and 4.7 of the Employment Agreement
that would have been payable in 2007 (the “2007 Payments”) if such Sections

4

 

	 	 	 	of the Employment Agreement had then been in effect, such 2007 Payments will be made under
this Letter Agreement in 2007 in accordance with Section 4.7 of the Employment Agreement (as
if such Section of the Employment Agreement had then been in effect), and you will receive a
lump-sum cash payment of the total amounts set forth in subparagraphs (a), (d) and (f)
above, minus the 2007 Payments (if any), on the later of (i) January 2, 2008 or (ii) the
first business day following the six month anniversary of the Separation Date.

	2.	 	For a period of twelve (12) months after the Separation Date, you, on behalf of yourself and
Indica Consulting Ltd. (“Indica”), agree to continue to comply with the covenants under
Sections 5.1, 5.2 and 5.3 of the Employment Agreement. If you breach your obligations under
Sections, 5.1, 5.2 or 5.3 of the Employment Agreement during such twelve-month period, the
Company will continue to have the rights to enforce such obligations under Section 5.4 of the
Employment Agreement and to seek the damages for such breach set forth in Section 5.5 of the
Employment Agreement. Notwithstanding the foregoing, it is understood by the Company that
during such twelve-month period (and thereafter) you will be the owner of a controlling equity
interest in Indica, will serve as a director and executive officer of Indica and will be
active in strategic planning and implementation, and the management and operation, of Indica’s
risk modeling, portfolio management and consulting businesses, including in such capacity
conducting business with PXRE and with persons and entities unaffiliated with PXRE (the
foregoing, collectively, the “Indica Activities”). The Company agrees that you may engage in
the Indica Activities provided that such engagement does not result in a breach of any of your
obligations under Sections 5.1, 5.2 or 5.3 of the Employment Agreement, except to the extent
that the Company consents to such breach.

5

 

	 	 	Any breach of such obligations by Indica shall be deemed to be a breach by you for purposes of
this Section 2.
	 
	3.	 	Cessation of all other Compensation and Benefits. From and after the Separation Date, and
except as otherwise expressly set forth in this Letter Agreement and in Sections 10 or 12 of
the Employment Agreement, you will not receive compensation, payments or benefits of any kind
from PXRE and you expressly acknowledge and agree that, from and after the Separation Date,
except with respect to the compensation, payments, benefits and rights expressly set forth in
this Letter Agreement and in Sections 10 and 12 of the Employment Agreement, you are not
entitled to any compensation, payment, benefit or right whatsoever, including, without
limitation, any right to payment under the sections of the Employment Agreement which do not
survive beyond the Separation Date as provided in paragraph 10 below, or under the Company’s
Amended and Restated Severance Plan for Certain Executives of PXRE Group Ltd., Severance Pay
Plan or 2004 Incentive Bonus Compensation Plan.
	 
	4.	 	Confidential Information. Except (i) as may be required by the lawful order of a court or
agency of competent jurisdiction, (ii) as is necessary or appropriate in connection with your
cooperation and assistance pursuant to paragraph 7 below, (iii) with respect to any
litigation, arbitration, mediation or investigation involving PXRE or this Letter Agreement,
including, without limitation, the enforcement of this Letter Agreement, (iv) as to
information which becomes known to the public or within the relevant trade or industry other
than due to your violation of this paragraph 4, and (v) to the extent that you have express
authorization from the Company, you, on behalf of yourself and Indica, hereby agree to keep
secret and confidential indefinitely all non-public information (including, without
limitation,

6

 

	 	 	information regarding any pending or threatened litigation, arbitrations or disputes) concerning
PXRE which was acquired by or disclosed to you during the course of your employment with PXRE,
and not to disclose same, either directly or indirectly, to any other person, firm or business
entity, or use it in any way. To the extent that you obtained information on behalf of PXRE
that, to your knowledge, is subject to attorney-client privilege as to PXRE’s attorneys, you
agree to take reasonable steps to maintain the confidentiality of such information and, to the
extent within your control, to preserve such privilege.
	 
	5.	 	Non-disparagement. You will not at any time after the Separation Date, whether in writing or
orally, knowingly publicly disparage, or demean in any way PXRE or its products, services,
officers, directors or employees. The Company will not, and will cause each of the Company’s
direct and indirect controlled subsidiaries and each of the Company’s and such controlled
subsidiaries’ respective officers and directors not to, at any time, whether in writing or
orally, knowingly publicly disparage or demean you in any way. Notwithstanding the foregoing,
nothing in this paragraph 5 will prevent any person from (x) responding publicly to incorrect,
disparaging, derogatory or demeaning public statements to the extent reasonably necessary to
correct or refute such public statement or (y) making any truthful statement to the extent (i)
necessary with respect to any litigation, arbitration, mediation or investigation involving
(A) PXRE or this Letter Agreement, including, but not limited to, the enforcement of this
Letter Agreement, or (B) any claims made by third parties that relate to your service as a
director or officer of the Company, including, without limitation, any litigation related to
the pending securities complaints that have been filed in the Southern District of New York by
Stephen Goldberger, Steve Klein, Ralph Lowry and Eldon Voss (the

7

 

	 	 	“Class Action Securities Actions”) or (ii) required by law or by any court, arbitrator, mediator
or administrative or legislative body (including any committee thereof) with apparent
jurisdiction to order such person to disclose or make accessible such information.
	 
	6.	 	Release. Each party to this Letter Agreement agrees to execute and deliver to the other
party the Mutual Release of Claims attached hereto as Exhibit A (the “Mutual Release”) on or
immediately following the Separation Date. A party which executes and delivers the Mutual
Release to the other party will be released from the provisions of this Section 6 (and the
Mutual Release executed and delivered by such party shall be of no force or effect) if, after
such party’s execution and delivery of the Mutual Release to the other party, the other party
does not deliver a fully executed counterpart of the Mutual Release within ten (10) days after
such other party’s receipt of the Mutual Release signed by the first party.
	 
	7.	 	Future Cooperation.

	 	(a)	 	You agree that, upon the Company’s reasonable request, you will use reasonable efforts
to assist and cooperate with the Company and the other Releasees in connection with the
defense or prosecution of any claim that may be made against or by the Company or any of
the other Releasees in their official capacities, or in connection with any ongoing or
future investigation or dispute or claim of any kind involving the Company or any of the
other Releasees in their official capacities, including any proceeding before any arbitral,
administrative, regulatory, self-regulatory, judicial, legislative, or other body or
agency; provided, however, that, any such assistance and cooperation requested by the
Company will take into account your business and personal commitments, and that you will
not be required to devote more than ten (10) business days per year to such assistance and

8

 

	 	 	 	cooperation, and, provided, if at the time of such assistance and cooperation you are not
employed or providing consulting services on a full-time basis (other than the Indica
Activities), you will be compensated at the rate of U.S. $350.00 per hour spent in such
activities.
	 
	 	(b)	 	To the extent possible, the Company will try to limit your participation under
subparagraph 7(a) above to regular business hours. In any event, (i) in any matter subject
to this paragraph 7, you will not be required to act against your best interests or the
best interests of any employer or business venture in which you are a partner or active
participant (including, without limitation, Indica) where the interest of your employer or
business venture are adverse to the interests of PXRE and (ii) any request for assistance
and cooperation will take into account the significance of the matters at issue in the
litigation, arbitration, proceeding or investigation. The Company agrees to provide you
with reasonable notice, to the extent practicable, in the event your assistance and
cooperation is required under this paragraph 7. The Company will reimburse you for the
reasonable expenses and costs actually incurred by you as a result of providing assistance
and cooperation under this paragraph 7, such reimbursement to be made as soon as
practicable after the receipt by the Company of the appropriate documentation evidencing
such expenses and costs. Such expenses and costs will include, without limitation,
demonstrably lost wages or other fees, travel costs and legal fees to the extent you
reasonably believe that separate representation is warranted, provided the Company is
notified in advance of the amount of such lost wages, costs and fees. Your entitlement to
reimbursement of such wages, costs and fees pursuant to this paragraph 7 will in no way
affect your rights to be indemnified and/or advanced expenses in accordance with the

9

 

	 	 	 	Company’s corporate documents, any applicable insurance policy, and/or in accordance with
this Letter Agreement (including pursuant to Sections 12.1, 12.2 and 12.3 of the Employment
Agreement).

	8.	 	Successors and Assigns. This Letter Agreement will inure to the benefit of and will be
binding upon the parties hereto and (i) with respect to the Company, its successors and
assigns, including, but not limited to, any entity with which the Company may merge or
consolidate or to which the Company may sell all or substantially all of its assets, (it being
agreed by the Company that it will cause any buyer of all or substantially all of its assets
or any such successor or assign to assume and agree to perform this Letter Agreement (and the
sections of the Employment Agreement which expressly survive the execution and delivery
hereof) in the same manner and to the same extent as the Company and that such sale ,
succession or assignment will not relieve the Company of its obligations hereunder or
thereunder) and (ii) with respect to you, your executors, administrators, heirs and legal
representatives. In the event of your death, all amounts due hereunder will be accelerated
and immediately paid to your estate.
	 
	9.	 	Severability; Headings. In the event that any provision of this Letter Agreement is held by
a court of proper jurisdiction to be invalid, void or voidable or otherwise unenforceable, the
balance of this Letter Agreement will continue in full force and effect unless such
construction would clearly be contrary to the intentions of the parties or would result in an
unconscionable injustice. The headings of the sections and paragraphs of this Letter
Agreement are for convenience of reference only and will not constitute a part hereof.
	 
	10.	 	Miscellaneous; Choice of Law. This Letter Agreement may be executed in several

10

 

	 	 	counterparts, each or which will be deemed to be an original but all of which together will
constitute one and the same instrument. This Letter Agreement constitutes the entire agreement,
and supersedes all prior agreements, of the parties hereto relating to the subject matter
hereof, including, without limitation, the Employment Agreement, which, subject to the following
proviso and subject to the provisions of paragraph 1(h) hereof, is hereby terminated and of no
further force or effect; provided that (i) Sections 1.1, 1.2, 2.1, 2.4, 2.5, 2.6 and 3 of the
Employment Agreement shall remain in full force and effect until the Separation Date and (ii)
the first sentence of Section 4.6.4, Sections 5.1, 5.2, 5.3, 5.4, 5.5 and 6 (subject to the
terms and conditions of Section 2 hereof), Sections 10(a) through (d) (and, for greater
certainty, it is agreed by the parties that the payments, compensation, benefits and
entitlements pursuant to paragraph 1 hereof shall be “Covered Payments” within the meaning of
Section 10(d)), and Sections 12.1, 12.2 and 12.3 of the Employment Agreement, shall each
survive the execution and delivery hereof and shall survive after the Separation Date and the
termination of the other provisions of the Employment Agreement. There are no written or oral
terms or representations made by either party with respect to the subject matter hereof other
than those contained herein and therein. This Letter Agreement (and the sections of the
Employment Agreement which expressly survive after the Separation Date) cannot be modified,
altered or amended except by a writing signed by all of the parties hereto. No waiver by any
party of any provision or condition of this Letter Agreement at any time will be deemed a waiver
of such provision or condition at any prior or subsequent time or of any provision or condition
at the same or any prior or subsequent time. This Letter Agreement will be governed by and
construed in accordance with the laws of Bermuda, without giving effect to any choice of law or
conflict of law provision or rule (whether of

11

 

	 	 	Bermuda or any other jurisdiction) that would cause the application of the laws of any
jurisdiction other than Bermuda.
	 
	11.	 	Remedies. In the event of a breach or threatened breach of paragraph 5 of this Letter
Agreement, you and the Company agree that the Company and you, as applicable, will be entitled
to injunctive or other equitable relief in a court of appropriate jurisdiction to remedy any
such breach or threatened breach, and you and the Company acknowledge that damages would be
inadequate and insufficient. The existence of this right to injunctive and other equitable
relief will not limit any other rights or remedies that you or the Company may have at law or
in equity including, without limitation, the right to monetary, compensatory and punitive
damages.
	 
	12.	 	Indemnification. The Company agrees that, for purposes of and without limiting Sections
12.1, 12.2 and 12.3 of the Employment Agreement, the conduct of activities pursuant to
paragraph 7 hereof will be covered by the provisions of such Sections and that you will be
indemnified, held harmless and reimbursed for and in respect of such activities to the extent
and subject to the terms and conditions set forth in such Section.
	 
	13.	 	Notices. For the purpose of this Letter Agreement, notices, demands and all other
communications provided for in this Letter Agreement will be in writing and will be sent by
messenger or overnight courier (provided in each case, confirmation of receipt is obtained),
certified or registered mail, postage prepaid and return receipt requested to the parties at
their respective addresses set forth below or to such other address as to which notice is
given.

12

 

If to you:

At the last address on the records of the Company

If to the Company:

PXRE Group Ltd.

PXRE House

110 Pitts Bay Road

Pembroke HM 08, Bermuda

With a copy to

PXRE Reinsurance Company

379 Thornall Street

Second floor

Edison, NJ 08837

Attn: General Counsel

Notices, demands and other communications will be deemed given on delivery thereof.

	14.	 	No Mitigation; No Offset. In no event will you be obligated to seek other employment or take
any other action by way of mitigation of the amounts payable under this Letter Agreement.
There will be no offset by the Company against your entitlements under this Letter Agreement
on account of any claim PXRE may have against you or for any compensation or other amounts
that you earn from subsequent employment or engagement of your services, including without
limitation, from or in connection with the Indica Activities.
	 
	15.	 	Company Representations. The Company represents and warrants that (i) the execution,
delivery and performance of this Letter Agreement by the Company has been fully and validly
authorized by all necessary corporate action, (ii) the officer signing this Letter

13

 

	 	 	Agreement on behalf of the Company is duly authorized to do so, (iii) the execution, delivery
and performance of this Letter Agreement by the Company does not violate any applicable law,
regulation, order, judgment or decree or any agreement, plan or document to which the Company is
a party or by which it is bound and (iv) upon execution and delivery of this Letter Agreement by
the parties, it will be the valid and binding obligation of the Company enforceable against it
in accordance with its terms, except to the extent that enforceability may be limited by
applicable bankruptcy, insolvency or similar laws affecting the enforcement of creditors’ rights
generally.
	 
	16.	 	Arbitration. Subject to the provisions of Section 11 above, any disputes arising under or in
connection with this Letter Agreement (and the sections of the Employment Agreement which
expressly survive the execution and delivery hereof) will be resolved by binding arbitration,
to be held in Hamilton, Bermuda, in accordance with the employment dispute rules and
procedures of the American Arbitration Association. Judgment upon the award rendered by the
arbitrator(s) may be entered in any court having jurisdiction thereof. Each party hereto will
bear his or its own costs of the arbitration or litigation, including, without limitation, his
or its attorneys’ fees.
	 
	17.	 	Definitions. For purposes of this Letter Agreement, “Good Reason” shall mean the
occurrence of any of the following events (without the your prior written consent): (a) a
decrease in the your current base salary, or a failure by the Company to pay material
compensation when due and payable to you in connection with your employment with the Company;
(b) the failure by the Company to promptly obtain an agreement from a successor to assume and
agree to perform this Letter Agreement in accordance with paragraph 8 above; (c) the Company’s
requiring you to be based at any office or location other than an office

14

 

	 	 	 	located in Bermuda or within fifty (50) miles of Manhattan; (d) any action by the Company that
materially reduces the fringe benefits or perquisites provided to you or your eligibility to
participate in any employee benefit plan of the Company unless you are provided with equal or
more favorable fringe benefits, perquisites or employee benefits, as the case may be; (d) the
assignment to you of any duties inconsistent in any respect with your position (including
status, offices, titles and reporting requirements), authority, duties or responsibilities as
contemplated by Section 1 of the Employment Agreement, other than an isolated, unsubstantial and
inadvertent action that is not taken in bad faith and is remedied by the Company within 10 days
after receipt of notice thereof given by you and other than any senior executive duties that may
be assigned to you in connection with the start-up and conduct of business by Peleus Reinsurance
Ltd. in accordance with the business plan therefor; and (e) any material breach of any
provision of this Letter Agreement (or of the sections of the Employment Agreement which survive
in accordance with paragraph 10 hereof) not covered by any other clause above. If any such Good
Reason is susceptible of cure, you may not resign for Good Reason unless you first give the
Company notice of your intention to resign and of the grounds for such resignation, and the
Company has not, within ten (10) business days following receipt of the notice, cured such Good
Reason, or in the event that such Good Reason is not susceptible to cure within such 10 business
day period, the Company has not taken all reasonable steps within such 10 business day period to
cure such Good Reason as promptly as practicable thereafter, but in no event less than 20
business days after such written notice from you. For purposes of this Agreement, “Cause” shall
mean: (a) any willful act or willful omission that constitutes a material breach by you of your
obligations under this Letter Agreement; (b) the willful and continued refusal of you to

15

 

	 	 	substantially perform the material duties required of you under this Letter Agreement; (c) any
willful material violation by you of any law or regulation applicable to the business of the
Company or any of its subsidiaries or affiliates; (d) your conviction of or plea of guilty or
nolo contendere to a felony or a crime involving moral turpitude, or any willful perpetration by
you of a common law fraud; or (e) any other willful misconduct by you that materially injures
the financial condition or business reputation of, or is otherwise materially injurious to, the
Company or any of its subsidiaries or affiliates. For purposes hereof, an action or inaction
will not be deemed to be willful if such is taken or omitted to be taken in the good faith
belief that such is in, or not opposed to, the best interests of PXRE. If the events giving
rise to Cause are susceptible to cure, the Company shall not terminate your employment hereunder
unless the Company first gives you written notice of its intention to terminate and of the
grounds for such termination, and you have not, within ten (10) business days following receipt
of the notice, cured the events giving rise to Cause. Except in the case of a conviction or
plea described in clause (d) above, no termination shall be treated as a termination for Cause
unless and until the Company Board shall have determined by a majority vote of its members that
Cause exists, after you have had an opportunity to be heard (with counsel of your choice) before
the Company Board.
	 
	18.	 	Withholding. The payment of any amount pursuant to this Letter Agreement shall be subject to
applicable withholding and payroll taxes, and such other deductions as may be required, if
any.
	 
	19.	 	Counterparts. This Letter Agreement may be executed in two or more counterparts. Signatures
delivered by facsimile or pdf shall be effective for all purposes.

16

 

	20.	 	409A. You and the Company agree that the terms and conditions hereof are intended by the
parties to comply with Section 409A of the Code and that, accordingly, you shall not report on
your personal income tax returns that any payment under Section 1 hereof will be subject to an
excise tax or an additional income tax by application of Section 409A of the Code. You shall
notify the Company in writing of any claim by the Internal Revenue Service that, if
successful, would require the payment by the Company of the gross-up payment under Section
10(d) of the Employment Agreement. Such notification shall be given as soon as practicable
but no later than thirty (30) business days after you receive written notification of such
claim and shall apprise the Company of the nature of such claim in reasonable detail and the
date on which such claim is requested to be paid. You shall not pay such claim prior to the
expiration of the thirty (30) day period following the date on which you give such notice to
the Company (or such shorter period ending on the date that any payment of taxes with respect
to such claim is due). If the Company notifies you in writing prior to the expiration of such
period that it desires to contest such claim, you shall: (i) give the Company all available
information reasonably requested by the Company relating to such claim; (ii) take such action
in connection with contesting such claim as the Company shall reasonably request in writing
from time to time, including, without limitation, accepting legal representation with respect
to such claim by an attorney selected by the Company and reasonably acceptable to you and/or
ceasing all efforts to contest such claim; (iii) cooperate in all reasonably respects with the
Company in good faith in order to effectively contest such claim; and (iv) permit the Company
to participate in any proceeding relating to such claim; provided, however,
that the Company shall bear and pay directly all reasonable costs and expenses (including
attorney fees and additional interest and penalties) incurred by you and it

17

 

	 	 	in connection with
such contest and, without limiting Section 10(d) of the Employment Agreement, shall indemnify
and hold you harmless, on an after-tax basis, from any excise tax or income tax (including
interest and penalties with respect thereto) and other costs, expenses or liabilities imposed
on you as a result of such contest, representation and payment of taxes, interest, penalties,
costs and expenses. Without limiting the foregoing provisions of this Letter Agreement, the
Company shall control all proceedings taken in connection with such contest, provided that
such is pursued in a diligent and professional manner, and, at its sole option, may pursue or
forego any and all administrative appeals, proceedings, hearings and conferences with the
taxing authority in respect of such claim and may, at its sole option, either direct you to
pay the tax claimed and sue for a refund or contest the claim in any permissible manner, and
you agree to prosecute such contest to a determination before any administrative tribunal, in
a court of initial jurisdiction and in one or more appellate courts, as the Company shall
determine and direct; provided, however, that if the Company directs you to
pay such claim and sue for a refund, the Company shall pay such claimed amount to you prior to
you making such payment, and, without limiting Section 10(d) of the Employment Agreement,
shall indemnify and hold you harmless, on an after-tax basis, from any excise tax or income
tax (including interest or penalties with respect thereto) imposed with respect to such
payment or with respect to any imputed income with respect to such payment; and
provided, further, that any extension of the statute of limitations relating
to payment of taxes for your taxable year with respect to which such contested amount is
claimed to be due is limited solely to such contested amount. Furthermore, the Company’s
control of the contest shall be limited to issues with respect to which a gross-up payment
would be payable hereunder and you shall be entitled, in your sole discretion, to settle or

18

 

	 	 	contest, as the case may be, any other issue raised by the Internal Revenue Service or any other
taxing authority. It is understood and agreed that nothing in this paragraph 20 shall require
you not to pay any tax (or interest and penalties thereon) imposed under Section 409A when due
or shall limit the Company’s obligations under Section 10(d) of the Employment Agreement,
including the Company’s obligation to pay you the 409A Gross-Up Payment (as defined in Section
10(d) of the Employment Agreement) prior to the date on which any excise tax or income tax (and
interest and penalties thereon) imposed by Section 409A is due to be paid.
	 
	21.	 	Acknowledgement and Acceptance of this Letter Agreement. For the avoidance of doubt, you
acknowledge and agree that this Letter Agreement shall not constitute a “notice of
termination” under the Employment Agreement, and you further acknowledge and agree that you
have received no such “notice of termination” prior to the date hereof. If this Letter
Agreement conforms to your understanding and is acceptable to you, please indicate the
acceptance hereof by signing and dating the enclosed copy of this Letter Agreement where
indicated and returning it by mail or personal delivery to:

Robert P. Myron

Chief Financial Officer

PXRE Group Ltd.

PXRE House

110 Pitts Bay Road

Pembroke HM 08, Bermuda

Sincerely,

19

 

PXRE GROUP LTD.

			
	By:	 	/s/  Robert P. Myron
 
Robert P. Myron
Executive Vice President & Chief Financial Officer

THIS LETTER AGREEMENT IS A LEGAL DOCUMENT. YOU SHOULD CONSULT WITH AN ATTORNEY PRIOR TO SIGNING
THIS LETTER AGREEMENT.

BY SIGNING THIS LETTER AGREEMENT YOU ACKNOWLEDGE THAT YOU ARE COMPETENT, THAT YOU HAVE BEEN
PROVIDED WITH THE OPPORTUNITY TO REVIEW AND CONSIDER THIS LETTER AGREEMENT WITH AN ATTORNEY OF YOUR
CHOICE AND YOU HAVE USED SUCH REVIEW PERIOD TO THE EXTENT YOU DESIRED, THAT YOU HAVE READ AND
UNDERSTAND AND VOLUNTARILY ACCEPT THIS LETTER AGREEMENT AS FULLY AND FINALLY RESOLVING, WAIVING AND
RELEASING ANY AND ALL CLAIMS WHICH YOU MAY HAVE AGAINST THE COMPANY AND RELEASEES (AS DEFINED
HEREIN) ON THE DATE HEREOF, THAT NO PROMISES OR INDUCEMENTS HAVE BEEN MADE TO YOU EXCEPT AS SET
FORTH IN THIS LETTER AGREEMENT, AND THAT YOU HAVE SIGNED THIS LETTER AGREEMENT FREELY AND
VOLUNTARILY, INTENDING TO BE LEGALLY BOUND BY ITS TERMS. THE FOREGOING IS A SUMMARY DESCRIPTION OF
THE GENERAL IMPORT OF THIS INSTRUMENT AND DOES NOT ALTER OR AMEND THE DETAILED PROVISIONS CONTAINED
IN THE BODY HEREOF.

20

 

	 	 	 
	ACCEPTED AND AGREED:
	 	 
	 
	 	 
	/s/ Jeffrey L. Radke

	 	Date: March 14, 2007
	 

Jeffrey L. Radke
	 	 

21EX-10.10

 

[*CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK
[***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.]

Exhibit 10.10

Commercial Supply Agreement

-By and Between-

Precision Pharma Services, Inc.

&

Javelin Pharmaceuticals, Inc.

For

Diclofenac Sodium (75mg/2mL) Injection

(DylojectTM Injection)

 

 

Table of Contents

	 	 	 	 	 	 	 
	Section	 	Title	 	Page
	1.

	 	DEFINITIONS
	 	 	2	 
	 
	2.

	 	TERM AND TERMINATION OF AGREEMENT
	 	 	4	 
	 
	3.

	 	GENERAL OBLIGATIONS
	 	 	7	 
	 
	4.

	 	OWNERSHIP
	 	 	9	 
	 
	5.

	 	PURCHASE ORDERS AND DELIVERIES
	 	 	9	 
	 
	6.

	 	PURCHASE PRICE AND PAYMENT TERMS
	 	 	12	 
	 
	7.

	 	COVENANTS, WARRANTIES AND REPRESENTATIONS
	 	 	13	 
	 
	8.

	 	QUALITY ASSURANCE, QUALITY CONTROL AND INSPECTIONS
	 	 	15	 
	 
	9.

	 	ADVERSE DRUG EXPERIENCES AND PRODUCT COMPLAINT
REPORTS
	 	 	16	 
	 
	10.

	 	CONFIDENTIALITY
	 	 	17	 
	 
	11.

	 	INDEMNIFICATION
	 	 	18	 
	 
	12.

	 	INSURANCE
	 	 	19	 
	 
	13.

	 	DISPUTE RESOLUTION
	 	 	21	 
	 
	14.

	 	RECALL
	 	 	21	 
	 
	15.

	 	NOTICES AND MISCELLANEOUS TERMS
	 	 	22	 
	 
	Schedule 1.15

	 	Product Specifications
	 	 	27	 
	 
	Schedule 1.3

	 	Javelin Pharmaceuticals Inc., Components
	 	 	28	 
	 
	Schedule 6.1

	 	Product Description and Purchase Price
	 	 	29	 
	 
	Schedule 6.7

	 	Itemized Supplemental Service Fees
	 	 	30	 

1

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

COMMERCIAL SUPPLY AGREEMENT

     This Commercial Supply Agreement (this “Agreement”) is entered into this 15th day
of February, 2007, (the “Agreement Date”) by and between JAVELIN PHARMACEUTICALS, INC.,
(hereinafter referred to as “Javelin”) and PRECISION PHARMA SERVICES, INC., 155 Duryea Road,
Melville, New York, 11747 USA (hereinafter referred to as “PPS”) (each individually a “Party” and
collectively, the “Parties”).

WITNESSETH:

     WHEREAS, Javelin desires to engage PPS to manufacture, bulk sterile filter, aseptic fill,
inspect, and supply the Javelin product known as DiclofenacTM in a 75mg/2mL injection; and

     WHEREAS, PPS possesses the facilities, know-how and skills to accomplish such manufacture,
bulk sterile filtering, aseptic filling, inspecting, and supplying desired by Javelin on the terms
and subject to the conditions set forth herein.

     NOW, THEREFORE, in consideration of the premises, mutual covenants, promises and agreements
set forth herein, and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties hereby agree as follows:

1. DEFINITIONS

	1.1.	 	“Adverse Drug Experience” shall have the meaning given in 21 C.F.R. § 314.80(a).
	 
	1.2.	 	“Affiliate” shall mean with respect to either Party, any Person that directly or indirectly
controls, is controlled by, or is under common control with, such Party. For purposes of this
definition, “control” of another Person shall mean ownership, or direct or indirect control,
of at least 50% of the voting stock or other ownership interest of the other Person, or direct
or indirect possession of the power to direct or cause the direction of the management and
policies of the other Person by any means whatsoever.
	 
	1.3.	 	“Annual Minimums” shall have the meaning set forth in Section 5.2.
	 
	1.4.	 	“Components” shall mean the direct materials purchased by Javelin or by PPS for the
Processing of Product, including without limitation the following materials: (a) active drug
product, excipients (b) 2mL glass vial, 13mm rubber stopper, 13mm flip top aluminum seal, and
(c) such other materials as specified in Schedule 1.3.
	 
	1.5.	 	“Dispute” shall have the meaning set forth in Section 13.1.

2

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED
WITH AN ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	1.6.	 	“Equipment” shall mean the equipment specified in Schedule 1.3 that Javelin has purchased
and delivered to PPS or that PPS has purchased and for which PPS has been reimbursed by
Javelin.
	 
	1.7.	 	“Event of Force Majeure” shall have the meaning given in Section 15.2.
	 
	1.8.	 	“FDA” shall mean the United States Food and Drug Administration.
	 
	1.9.	 	“EMEA” shall mean the European Medicines Agency.
	 
	1.10.	 	“Firm Purchase Order” shall mean a purchase order submitted to PPS by Javelin and accepted
by PPS in accordance with Section 5.4.
	 
	1.11.	 	“Good Manufacturing Practices” shall mean current good manufacturing practices that are
applicable to the Product and the Processing thereof, as defined in 21 C.F.R. Parts 210 and
211, as amended from time to time, and regulations governed by the European Union (EU).
	 
	1.12.	 	“Invention” shall mean any invention, discovery, process, product or design, and any
improvements to any of the foregoing, used, conceived, created, developed or reduced to
practice as a result of, or arising from or during, the Processing of Product by PPS.
	 
	1.13.	 	“Batch Records” shall mean master production and control records for the Product, as defined
in 21 C.F.R. § 211.186.
	 
	1.14.	 	“NDA” shall mean a New Drug Application or an Abbreviated New Drug Application as defined in
21 U.S.C. § 355.
	 
	1.15.	 	“MAA” shall mean a Marketing Authorization Application.
	 
	1.16.	 	“Monthly Maximum” shall have the meaning set forth in Section 5.3.
	 
	1.17.	 	“Person” shall mean an individual, corporation, partnership, limited liability company,
trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole
proprietorship, incorporated organization, governmental authority or any other form of entity.
	 
	1.18.	 	“Process” or “Processing”, as the context requires, shall mean the services provided by PPS
hereunder, such as bulk drug formulation, sterile filtration, aseptic filling, inspecting and
testing of the Product, in strict conformance with the Process Specifications.
	 
	1.19.	 	“Process Specifications” shall mean the critical process parameters for manufacturing
Product as defined in the Batch Record.

3

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	1.20.	 	“Product” shall mean DylojetTM (or other Diclofenac Sodium injectable) manufactured by
PPS on behalf of Javelin in conformance with the Process Specifications, Good Manufacturing
Practices, and Standard Operating Procedures.
	 
	1.21.	 	1.18 “Product Specifications” shall mean the initial specifications set forth in Schedule 1.15.
	 
	1.22.	 	1.19 “Standard Operating Procedures” shall mean the standard operating procedures established by PPS generally, and
for the Processing of the Product in compliance with Good Manufacturing Practices specifically.
	 
	1.23.	 	“Third Party Laboratory” shall have the meaning set forth in Section 3.5.
	 
	1.24.	 	“Effective Date” shall mean April 1, 2007.

2. TERM AND TERMINATION OF AGREEMENT

	2.1.	 	Term. This Agreement shall commence on the Agreement Date and, unless terminated
earlier pursuant to this Article 2, shall continue for twenty four (24) months (“Initial
Term”) from the Effective Date. Thereafter, this Agreement shall be renewed automatically for
successive periods of one (1) year each (each a “Renewal Term”), unless either Party gives
written notice to the other Party of its intention not to renew this Agreement not less than
two hundred and seventy (270) days prior to the end of the Initial Term or any Renewal Term.
The Initial Term and any Renewal Terms are referred to collectively herein as the “Term”.
	 
	2.2.	 	Termination. This Agreement may be terminated as follows:

	 	(a)	 	This Agreement may be terminated by either Party if the other Party is in
material breach of any provision of this Agreement and such other Party has not cured
such breach within ninety (90) days of receiving written notice thereof; provided,
however, that PPS may terminate this Agreement upon written notice to Javelin in the
event that Javelin fails to make any payment due hereunder within thirty (30) days of
receiving written notice from PPS that such payment is past due.
	 
	 	(b)	 	This Agreement may be terminated by either Party upon sixty (60) days’ prior
written notice to the other Party at any time during the Term if the other Party: (i)
files in any court pursuant to any statute of any government a petition in bankruptcy
or insolvency or for reorganization or for an arrangement or for the appointment of a
receiver or trustee of the Party or of its assets; (ii) proposes a written agreement
of composition for extension of its debts; (iii) is served with an involuntary petition against it,
filed in any insolvency proceeding, and such

4

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	petition is not dismissed within sixty (60) days after filing thereof; or (iv)
makes an assignment for the benefit of its creditors.

	 	(c)	 	This Agreement shall automatically terminate if the Product is permanently
and completely withdrawn from all markets for serious adverse health or safety
reasons.
	 
	 	(d)	 	PPS Obligations. If after twelve (12) months, or prior to the first
manufacture of Product by PPS (whichever occurs first), PPS fails to meet its
performance obligations with regards to the manufacture Product in accordance with
cGMP then Javelin may elect to terminate the agreement.

	2.3.	 	PPS’s Obligations Upon Expiration or Termination. Upon expiration or termination of
this Agreement for any reason, unless otherwise provided in this Article 2, PPS shall cease
and refrain from Processing the Product for Javelin and shall perform the actions set forth
below, provided that such actions may be delayed to the extent necessary for PPS to fulfill
any Firm Purchase Orders outstanding as of the date of such expiration or termination.

	 	(a)	 	Return to Javelin at Javelin’s request and expense, all confidential and
proprietary information or documents supplied by Javelin to PPS and all original
technical data and technology provided by Javelin to PPS, and shall make no further
use of such confidential or proprietary information except as permitted herein.
Notwithstanding the foregoing, PPS may retain for archival purposes one copy of all
such information; documents, data and technology.
	 
	 	(b)	 	Return to Javelin at Javelin’s expense, all inventory in PPS’s possession of
the Product and Javelin Components (including, without limitation, all
work-in-progress), excluding such amounts of Product and Javelin Components as are
required by PPS in order to fulfill all Firm Purchase Orders outstanding as of the
date of such expiration or termination.
	 
	 	(c)	 	Return to Javelin, at Javelin’s expense, all Equipment that is in PPS’s
possession as of the date of such expiration or termination.
	 
	 	(d)	 	Reimburse Javelin for all expenses incurred by Javelin relating to the return
to PPS of all confidential and proprietary information pursuant to Section 2.4(a).

	2.4.	 	Javelin’s Obligations Upon Expiration or Termination. Upon expiration or termination
of this Agreement for any reason, unless otherwise provided in this Article 2, Javelin shall:

5

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	(a)	 	Return to PPS, at PPS’s request and expense, all confidential and proprietary
information or documents supplied by PPS to Javelin and all original technical data
and technology provided by PPS to Javelin and shall make no further use of such
confidential or proprietary information except as permitted herein. Notwithstanding
the foregoing, Javelin may retain for to the extent necessary for legal archival
purposes only one copy of all such information, documents, data and technology.
	 
	 	(b)	 	Reimburse PPS for all expenses incurred by PPS relating to the return to
Javelin of all confidential and proprietary information pursuant to Section 2.3(a),
all Product and Javelin Components pursuant to Section 2.3(b) and all Equipment
pursuant to Section 2.3(c).
	 
	 	(c)	 	Pay all outstanding invoices and other accrued payments owed by Javelin to
PPS up to and including the date of such expiration or termination (“Outstanding
Obligations”), and all amounts owed by Javelin pursuant to Section 2.3(c), unless any
such invoice or other accrued payment is the subject of a good faith dispute between
the parties.
	 
	 	(d)	 	If after the Initial Term, except in the case of termination by Javelin for
PPS’s uncured material breach, pay to PPS, not as a penalty, an amount equal to (i)
the Annual Minimums pursuant to Section 5.2 times (iii) the price per unit set forth
in Schedule 6.1 less (iii) money actually paid during the period covered by the
unfulfilled Annual Minimum(s)and any Outstanding Obligations.
	 
	 	(e)	 	Notwithstanding anything to the contrary set forth in this Agreement, in the
event that PPS supplies Javelin with Product during the period between the giving of
any notice of termination pursuant to this Article 2 and the effective date of such
termination, Javelin shall pay for such Product on a COD basis. This paragraph 2.4(f)
shall not apply if the Agreement herein is set to expire based upon non-renewal.
	 
	 	(f)	 	Javelin shall purchase within one hundred twenty (120) days after the
expiration or termination of this Agreement PPS’s inventory of Product at the price
per Product set forth on Schedule 6.1.

	2.5.	 	No Effect. Expiration or termination of this Agreement shall not affect the
following:

	 	(a)	 	The obligation of Javelin to pay to PPS all outstanding invoices and other
accrued payments owed to PPS by Javelin hereunder through the date of such expiration
or termination, except to the extent that a good faith dispute over such invoices
exists.

6

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	(b)	 	The obligation of each Party otherwise to fulfill all obligations to the other
Party hereunder that arose prior to the date of such expiration or termination.
	 
	 	(c)	 	Any obligation hereunder that expressly survives expiration or termination,
including without limitation those set forth in Articles 10, 11, 12, 13 and 14.
	 
	 	(d)	 	The remedies of either Party otherwise available to it at law or in equity in
relation to any rights accrued under this Agreement prior to such expiration or
termination.

3. GENERAL OBLIGATIONS

	3.1.	 	Javelin Responsibility. Upon release of Product to Javelin, Javelin is responsible
for: (i) labeling and packaging of Product; (ii) release of the final Product for sale or
distribution in accordance with all applicably; laws; (iii) any stability testing program
relating to the Product; (iv) retaining and maintaining any samples of the Product at the PPS
facility or elsewhere as may be specified by Javelin; and (v) obtaining the required Drug
Listing for the Product and providing a copy of Drug Establishment Regulatory Form 2656 to PPS
promptly after the Product is approved for marketing by the FDA and/or EMEA for European
distribution.
	 
	3.2.	 	Product Registration. Javelin shall be solely responsible for obtaining, maintaining
and monitoring the registration of the Product with the FDA and other applicable regulatory
authorities. PPS shall use commercially reasonable efforts to provide to Javelin such
documentation reasonably requested by Javelin relating to PPS’s Processing of Product to
support Javelin’s submission to the FDA of an NDA and to the EMEA of an MAA for the Product.
PPS shall provide such documentation in accordance with timelines agreed to by both Parties.
PPS shall use commercially reasonable efforts to cooperate with the FDA or any other
applicable regulatory authority in the event that such authority requires additional
information from PPS relating to PPS’s Processing of Product. Javelin shall be solely
responsible for all expenses associated with Product-specific validation work.
	 
	3.3.	 	Facility Permits. In the event that a regulatory authority imposes any requirements
on PPS not in existence as of the Effective Date with respect to permits, licenses or
certifications for any facility where PPS performs Processing, PPS shall bear such expenses
necessary in order for PPS to comply generally with Good Manufacturing Practices, and Javelin
shall bear such expenses that are incurred only as a result of PPS’s performance of Processing
for Javelin.
	 
	3.4.	 	Client Components. At Javelin’s sole discretion, either Javelin will procure all
necessary Javelin Components and shall send to PPS in amounts and on a schedule as PPS may
direct and that are reasonably correlated to any outstanding purchase orders, or

7

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	at Javelin’s direction PPS shall purchase such components and invoice Javelin for all
costs, plus ten percent (10%) mark-up, incurred. If Javelin elects to have PPS procure
Javelin Components, PPS shall utilize the same standard of care it uses when purchasing
materials for itself and will utilize commercially reasonable efforts to obtain the best
terms possible. In the event that Javelin elects or directs PPS to purchase quantities in
excess of what PPS requires pursuant to outstanding purchase orders and desires PPS to
store such components, then the Parties will negotiate reasonable terms to cover PPS’s cost
of storage and other related expenses.

	3.5.	 	Javelin Testing. PPS shall test and inspect each lot of Product for conformance with
the Product Specifications applicable thereto prior to shipment of such Product to Javelin.
After receipt thereof, Javelin shall test and inspect each lot for conformance with the
Product Specifications, (including all product documentation), using test methods described in
the Product Specifications. If within sixty (60) days after receipt of any lot of Product by
Javelin, Javelin notifies PPS in writing that such lot does not conform to the Product
Specifications and Process Specifications have been met, Javelin shall pay PPS the per vial
price set forth in Schedule 6.1. If within sixty (60) days after receipt of any lot of Product
by Javelin, Javelin notifies PPS in writing that such lot does not conform to the Product
Specifications as a result of deviation from the Process Specifications and as determined by
Javelin’s testing and inspection of such Product, PPS shall retain the per vial price set
forth in Schedule 6.1 and manufacture a replacement batch at PPS’s expense within ninety (90)
days after PPS’s confirmation that such Product is non-conforming. PPS shall have thirty (30)
days to determine such confirmation or refer the matter to [***] (“Third Party Laboratory”).
PPS reserves the right to have each lot of Product tested by the Third Party Laboratory if the
Parties disagree as to whether the Product is non-conforming. If the Third Party Laboratory
determines that the Product does meet Product Specifications, then the cost of such testing
shall be borne by Javelin, otherwise costs to be borne by PPS. The determination of the Third Party
Laboratory with respect to Product conformance shall be final and binding on both parties.
In the event that Product does not conform to Product Specifications as a result of
deviation from the Process Specifications, PPS shall deliver replacement Product to Javelin
at PPS’s expense. Javelin shall, at PPS’s option, direction, and expense, either (a) return
non-conforming Product to PPS or (b) destroy non-conforming Product in accordance with all
applicable laws and regulations. Javelin shall be deemed to have accepted each lot of
Product with respect to which it does not notify PPS in writing of any non-conformity
within sixty (60) days after its receipt thereof. Upon agreement by PPS, or determination
by Third Party Laboratory, that a Product is non-conforming, Javelin and PPS shall conduct
a good faith investigation into the reasons for such non-conformance. PPS shall make
commercially reasonable efforts to provide Javelin, and/or its designee(s), with access to
the facility in which the Product was manufactured, all

8

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	manufacturing equipment, and all relevant documentation and records, to determine
whether there has been a deviation from the Process Specifications.

4. OWNERSHIP

	4.1.	 	Ownership of Product. Except as otherwise provided herein, Javelin shall own all
right, title and interest in and to the Product, including without limitation all patent,
copyright, trademark, trade secret and other proprietary rights therein. Javelin hereby grants
to PPS, and PPS hereby accepts, a non-exclusive, worldwide, royalty-free license to use or
practice, as applicable, such patent, copyright, trademark, trade secret and other proprietary
rights of Javelin as necessary to fulfill PPS’s obligations under this Agreement.
	 
	4.2.	 	Javelin’s Trademarks. PPS acknowledges and agrees that the trademarks, trade names,
trade dress, labels, labeling and designs used or to be selected by Javelin for use in
connection with the Product are the property of Javelin and that PPS shall have no rights in
or to such trademarks, trade names, trade dress, labels, labeling or designs except as
necessary to fulfill its obligations hereunder.
	 
	4.3.	 	Ownership of Inventions. PPS shall own all right, title and interest in and to
inventions, including without limitation all patent, copyright, trademark, trade secret and
other proprietary rights therein that arise as a result of ideas developed or work performed
by PPS during this contract. Javelin shall own all right, title and interest in and to
Inventions, including without limitation all patent, copyright, trademark, trade secret and
other proprietary rights therein that arise as a result of work specifically requested by, or at the direction of, Javelin during this
contract.
	 
	4.4.	 	PPS’s Trademarks. Javelin acknowledges and agrees that trademarks and trade names
used by PPS are the property of PPS and that Javelin shall have no rights in or to such
trademarks or trade names.

5. PURCHASE ORDERS AND DELIVERIES

	5.1.	 	Forecast. Unless otherwise agreed to by the Parties, not less than six (6) calendar
months prior to the initial shipment date for the first order of Product hereunder, Javelin
shall submit to PPS a forecast of the batch quantities of Product that Javelin expects to
order for delivery during the twelve (12) months following such initial shipment date.
Thereafter, no later than thirty (30) days before the start of each subsequent calendar month,
Javelin shall submit to PPS a twelve (12) month revised forecast estimating the quantity of
Product that Javelin expects to order for delivery during the following twelve

9

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	(12) month period. The twelve (12) month rolling forecasts provided for in this
Section 5.1 of which the first six (6) months of any rolling forecast will be binding and
purchase orders will be issued for each month of the binding forecast and the remaining six
(6) months shall not be binding and will be used by PPS for planning purposes only.
	 
	5.2.	 	Minimum Quantities. During the first twenty four (24) months following the Effective
Date, Javelin shall place firm orders for [***] (“Annual Minimums”) to be manufactured and
delivered during such periods on a take or pay basis. In the event that Javelin does not order
during any twelve month period the applicable Annual Minimum, then it shall be obligated to
pay PPS within thirty (30) days the difference in amounts actually paid during that period and
what would have been paid had the Annual Minimum commitment been met.
	 
	5.3.	 	Monthly Maximum. During the Term, after the date that the FDA or EMEA approves the
NDA or the MAA for the Product, Javelin’s requirements for the Product that it orders from PPS
shall be [***] units of Product per month (“Monthly Maximum”). In the event that Javelin
anticipates the need for more than this maximum amount, PPS shall use commercially reasonable
efforts to increase its capacity to meet such excess demand.
	 
	5.4.	 	Annual Minimum Product Manufacturing Capacity. PPS guarantees to Javelin that PPS
will have capacity during each Product contract year to fill orders for the manufacture and
delivery equal to the Annual Minimum quantity pursuant to Section 5.2. In the event Javelin anticipates that it will require Product in excess of
the Annual Minimum Manufacturing Capacity during any Product contract year, it shall so
notify PPS as it so determines.
	 
	5.5.	 	Receipt of Purchase Order. PPS’s obligation to Process and supply any specific
quantity of Product shall be contingent upon the submission by Javelin and acceptance by PPS,
of a written purchase order in accordance with the terms of this Article 5. Each purchase
order submitted by Javelin shall set forth the quantity of Product to be purchased, the
delivery and shipping instructions and delivery schedule thereof. Unless PPS’s prior written
approval states otherwise, Javelin shall use commercially reasonable efforts to allocate its
annual purchases evenly over each month and in no case shall any one month order exceed the
Monthly Maximum.
	 
	5.6.	 	Purchase Order Acceptance. Purchase orders placed with PPS by Javelin may be
accepted by PPS for each month of production and will be reviewed by PPS within fourteen (14)
days after PPS’s receipt. PPS shall make commercially reasonable efforts to supply Javelin
with Product as requested in a purchase order. Each purchase order shall become a firm order
and binding on PPS only upon acceptance by PPS of such purchase order in accordance with the
terms of this Section 5.4 (each such accepted purchase order

10

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	a “Firm Purchase Order”). If PPS does not reject a purchase order within the fourteen
(14) day period after receipt, the order shall be considered to be accepted. PPS will be
deemed to have satisfied each Firm Purchase Order if the quantity of Product supplied is
not more than 110% and not less than 90% of the quantity ordered by Javelin. In the event
of any conflict between the terms and conditions of this Agreement and the terms and
conditions of any Firm Purchase Order, the terms and conditions of this Agreement shall
control.
	 
	5.7.	 	Lead Time. Each Firm Purchase Order shall require a shipment date for the first
shipment of Product there under not less than one hundred and eighty (180) days from the date
of such Firm Purchase Order. Delivery dates set forth in Firm Purchase Orders will be deemed
to be estimated dates only.
	 
	5.8.	 	Delivery. Javelin shall arrange for delivery of Product to Javelin from PPS’s
Melville plant in accordance with the instructions in the relevant Firm Purchase Order. Each
Firm Purchase Order shall designate one single delivery location within the continental United
States. At Javelin’s request, PPS shall include on packaging slips for the Product the Firm
Purchase Order number or other identifying number specified by Javelin. All deliveries shall
be EXW (PPS’s Melville plant) (Incoterms 2000). Javelin shall be solely responsible for all
shipping costs, including without limitation all freight, insurance charges, taxes, import
and export duties, inspection fees and other charges applicable to the sale and transport
of Product supplied by PPS hereunder. Javelin shall comply with all export laws,
restrictions and regulations of any U.S. or foreign agency or authority, and shall not
export or re-export the Product, or any materials or technology derived from the Product,
in violation of any such laws, restrictions, or regulations, or without all necessary
approvals. Without limiting the generality of the foregoing, Javelin shall not export or
re-export the Product, or any materials or technology derived from the Product, to any
proscribed country, party or entity listed in the applicable laws, regulations and rules of
the U.S. government unless properly authorized.
	 
	5.9.	 	Changes to Firm Purchase Orders. Except as otherwise expressly provided in this
Agreement, there shall be no modification or cancellation of any Firm Purchase Order except by
mutual written agreement of the Parties; provided, however, that in the event that PPS accepts
a purchase order from Javelin for an aggregate amount of Product to be shipped in any month
that exceeds by one (1) batch or one-hundred percent (100%) or more the amount specified in
the most recent forecast covering such month provided pursuant to Section 5.1, there shall be
a commercially reasonable extension of the time periods for delivery of such Product by PPS,
if requested by PPS.

11

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

6. PURCHASE PRICE AND PAYMENT TERMS

	6.1.	 	Purchase Price. In consideration of the Processing to be performed by PPS hereunder,
Javelin shall pay to PPS the price per Product as set forth on Schedule 6.1, subject to
escalation as provided in Section 6.2. Javelin shall pay such price for all Product delivered
hereunder (e.g., for samples of Product as well as for Product destined for commercial sale).
	 
	6.2.	 	Price Escalator Formula. The Product prices set forth on Schedule 6.1 hereto shall
be adjusted at the start of the first Renewal Term following the Effective Date, and on each
subsequent January 1st thereafter during a Renewal Term to reflect the percentage
increase in the inflation rate for the [***] period ending on December 31st, as measured by
the Consumer Price Index (CPI for Pharmaceutical Products) issued by the Bureau of Labor
Statistics, U.S. Department of Labor.
	 
	6.3.	 	Product Specification or Process Specification Changes. In the event that the
Parties agree to modify the Product Specifications or Process Specifications, PPS
shall advise Javelin as to any proposed price adjustments that would result from such
modification. The Parties shall negotiate in good faith to reach agreement on the adjusted
price for PPS’s supply of the Product based on such modified Product Specifications or
Process Specifications, giving due consideration to the effect of such modification, on
PPS’s costs in performing Processing. Notwithstanding anything to the contrary set forth in
this Agreement, PPS shall have no obligation to supply Products based on modified Product
Specifications or Process Specifications if the Parties do not agree on a mutually
acceptable price adjustment.
	 
	6.4.	 	Invoices. PPS shall send all invoices to a single address specified in writing by
the Javelin. All invoices to Javelin shall be stated and payable in United States dollars and
shall indicate the quantity of Product shipped to Javelin pursuant to Firm Purchase Orders
during the period stated on such invoice, and the price for the Product covered by such
invoice.
	 
	6.5.	 	Remittance. Javelin shall pay all amounts stated in each invoice to PPS within
thirty (30) days of the date of such invoice, without any offset or deduction of any nature
whatsoever. In the event that Javelin fails to pay all or any part of any invoice on the due
date thereof, and PPS elects not to terminate Agreement pursuant to Section 2.2 (a), Javelin
shall pay interest on the unpaid amount at an annual rate equal to 1.5% above the lowest prime
rate as published in The Wall Street Journal on or nearest to such due date, which
interest will accrue from such due date through the date such unpaid amount is paid in full.

12

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	6.6.	 	Taxes. Javelin shall be solely responsible for paying all taxes, levies, duties
or fees of any kind, nature or description whatsoever (except for taxes based on PPS’s net
income or gross receipts) applicable to the Processing or transportation of Product hereunder.
	 
	6.7.	 	Supplemental Costs. Costs for supplemental services, as requested by Javelin and to
the extent reasonably available from PPS, to be paid by Javelin are shown in Schedule 6.7.
These services may include, documentation, validation, Quality/Compliance, Engineering and
Analytical services. PPS shall invoice Javelin monthly for such services, and payment shall be
due net thirty (30) days after the date of invoice and otherwise as set forth in Section 6.5.

7. COVENANTS, WARRANTIES AND REPRESENTATIONS

	7.1.	 	PPS Covenants and Warranties.

	 	(a)	 	GMPs and SOPs. PPS covenants and warrants that the Product purchased
by Javelin hereunder shall be Processed in all material respects in accordance with
Good Manufacturing Practices, Standard Operating Procedures, and the terms and
conditions of this Agreement.
	 
	 	(b)	 	Adulteration and Misbranding. PPS covenants and warrants that as of
the time that Products are made available to Javelin, such Products will not be
adulterated or misbranded, and will not be articles that could not, under the
provisions of the Federal Food, Drug and Cosmetic Act, be introduced into interstate
commerce, or under the provisions of the European Union be introduced into commerce in
the EU. For purposes of this Section 7.1(b), “adulterated” shall have the meaning
given in 21 U.S.C. § 351, and “misbranded” shall have the meaning given in 21 U.S.C. §
352. The covenant and warranty set forth in this Section 7.1(b) shall not apply if
such adulteration, misbranding, or inability to be introduced into interstate commerce
results from the use of Javelin Components.
	 
	 	(c)	 	Deviations from Product Specifications. PPS warrants that there will
be no deviations from the Product Specifications as a result of PPS’s negligence.

	7.2.	 	Javelin Pharmaceuticals Inc. Covenants and Warranties.

	 	(a)	 	Client Components. If PPS procures Components, PPS shall test and
release all Components used in the manufacture of Javelin’s product in accordance with
Good Manufacturing Practices. In the event that Javelin supplies and tests components,
Javelin covenants and warrants that any Components supplied to

13

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	PPS by Javelin shall be manufactured in accordance with Good Manufacturing
Practices and the terms and conditions of this Agreement.
	 
	 	(b)	 	Use of Products. Javelin covenants and warrants that it shall hold,
store, handle, ship, deliver, distribute and sell the Products in accordance with Good
Manufacturing Practices and all other applicable laws.
	 
	 	(c)	 	No Claims. Javelin covenants and warrants that there are no adverse
actions, suits or claims pending or threatened against it or any of its Affiliates
with respect to the Product.

	7.3.	 	Mutual Representations and Warranties. In addition to the other representations and
warranties set forth in this Article 7, each Party represents and warrants to the other Party
that:

	 	(a)	 	Authorization. The execution, delivery and performance of this
Agreement by such Party have been duly authorized by all necessary action on the part
of such Party; and
	 
	 	(b)	 	Enforceability. This Agreement, when executed and delivered by such
Party in accordance with the provisions hereof, will be a legal, valid and binding
obligation of such Party, enforceable against such Party in accordance with its terms,
except as such enforceability may be limited by applicable bankruptcy, insolvency,
moratorium, reorganization or similar laws affecting the enforcement of creditors’
rights generally and by limitations on the availability of specific performance and
other equitable remedies against such Party; and
	 
	 	(c)	 	No Conflicts. Such Party’s execution, delivery and performance of
this Agreement shall not constitute a violation, breach or default under any contract,
instrument, obligation or agreement to which it is a party or by which it is bound and
will not conflict with or violate any applicable law, rule, regulation, judgment,
order or decree of any governmental agency or court having jurisdiction over it or its
assets or property.

	7.4.	 	NO OTHER WARRANTIES. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 7, PPS
MAKES NO WARRANTY OF ANY KIND WHATSOEVER, EXPRESS OR IMPLIED, AND ALL IMPLIED WARRANTIES, INCLUDING
WITHOUT LIMITATION THE WARRANTY OF FITNESS FOR A PARTICULAR USE OR PURPOSE AND THE WARRANTY OF
MERCHANTABILITY, ARE HEREBY DISCLAIMED BY PPS.

14

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH
SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

8. QUALITY ASSURANCE, QUALITY CONTROL AND INSPECTIONS

	8.1.	 	Batch Records. PPS shall include with each batch of Product delivered to Javelin a
complete copy of the applicable executed Batch Records including all testing results,
associated processing charts, printouts and certificates of analysis (which shall have been
reviewed and approved by PPS’s internal quality assurance department) relating to PPS’s
Processing of such Product. Javelin shall review and approve such Batch Records within sixty
(60) calendar days.

	8.2.	 	Deviations. PPS shall document in writing any deviation from Standard Operating
Procedures or the Product Specifications by means of a deviation report, which report shall be
attached to the Batch Records to which the report applies. PPS shall maintain a validation
program consistent with Good Manufacturing Practices. All investigations, OOSs, CAPAs, and
environmental excursions that may have an impact on any batch of Product or its components
must be included with the batch documentation, and must be provided in accordance with the
terms of the Quality Agreement.

	8.3.	 	Quality Control. PPS shall perform such quality assurance testing as it deems
necessary to maintain a quality control program consistent with Good Manufacturing Practices.

	8.4.	 	Loss of Product. Subject to PPS’s Limitation of Liability, any loss of Product or
Javelin Components during Processing that exceeds allowed production losses (as defined in the
Standard Operating Procedures and Batch Records) and that is not attributable to contingencies
beyond PPS’s reasonable control shall be for the account of and charged to PPS at a cost, in
respect of each batch of Product or Javelin Components, of [***], whichever is less. For
Product loss attributable to PPS not resulting from activities performed in the normal course
of Processing of Product, PPS shall be liable for [***] subject to PPS’s annual limitation of
liability.

	8.5.	 	Audits. Up to one time per month Javelin may choose to observe, or have its designee
observe, the manufacturing, inspection, testing or other related processing of a batch of
Javelin’s Product upon two (2) weeks communicated notice. Additional visits as required shall
be accepted by PPS for documentation and testing issues that affect any batch towards its
release. One time per year during each calendar year of the Term, Javelin shall have the
right, at its sole expense, upon not less than four (4) weeks’ prior written notice to PPS, to
inspect or audit, or have its designee inspect or audit, with its QP present, during normal
business hours those sections of PPS’s facilities used directly in, and documents relating
directly to PPS’s Processing of Product for Javelin (including all applicable PPS SOP’s), for
the purpose of monitoring PPS’s compliance with the previsions of this Agreement.
Notwithstanding the foregoing, PPS reserves the right to deny Javelin access to any facility
where there is a risk to health or safety or to the

15

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	security or quality of Products being Processed hereunder or any other products being
processed by PPS, provided that PPS shall provide access to such facility as soon as
practical.
	 
	8.6.	 	Governmental Inspection. In the event any relevant regulatory authority notifies PPS
of its intention to inspect PPS’s facilities specifically in connection with anything
associated with the manufacturing, testing, processing or otherwise, that may affect the
Javelin Product, PPS shall notify Javelin of such inspection immediately and shall supply
Javelin with copies of all relevant correspondence relating to such inspection. Javelin may
send representatives to such PPS facilities to participate in any such inspection at Javelin’s
expense. In the event PPS receives any communication from any relevant regulatory authority in
connection with PPS’s Processing of Product for Javelin hereunder that requires a response or
action by PPS, including, but not limited to, an FDA Form 483 (Inspectional Observations) or a
Warning Letter, PPS shall notify Javelin immediately, Javelin shall cooperate fully with PPS
in connection with PPS’s preparation of such response, and promptly shall provide PPS with all
data or other information required by PPS in preparing such response.

9. ADVERSE DRUG EXPERIENCES AND PRODUCT COMPLAINT REPORTS

	9.1.	 	Adverse Drug Experiences. Javelin shall be responsible for reporting to the FDA
and/or the MHRA, as required by applicable law, all Adverse Drug Experiences associated with
the Product. Within the period of time prescribed by applicable law after PPS becomes aware of
an Adverse Drug Experience, PPS shall notify Javelin of such Adverse Drug Experience.

	9.2.	 	Complaints. If Javelin receives any complaint associated with PPS’s Processing of
Product or PPS’s use of any Javelin Component, including without limitation a complaint from
the FDA’s MedWatch service, Javelin shall immediately notify PPS of such complaint by
telephone, and PPS shall provide a preliminary response in writing to Javelin regarding the
complaint within twenty four (24) hours after receiving the notification by Javelin, Javelin
shall have sole responsibility for responding to complaints associated with the Product or
Javelin Components, whether such complaints are received by Javelin or by PPS. Javelin shall
provide a written response on each complaint to each complainant, and shall provide
simultaneously a copy of such response to PPS.

	9.3.	 	Complaint Files. Javelin and PPS, as applicable, shall maintain complaint files in
accordance with Good Manufacturing Practices.

16

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

10. CONFIDENTIALITY

	10.1.	 	Confidentiality Obligation. During the Term and for a period of five (5) years
following the expiration or termination hereof, each Party (the “Recipient”) shall maintain in
confidence all information and materials disclosed by the other Party (the “Disclosing Party”)
and marked as confidential or which the Recipient knows are or contain trade secrets or other
proprietary information of the Disclosing Party including, without limitation, information
relating to the Processing of Product or the business plans of the Disclosing Party and
information provided by the Disclosing Party to the Recipient prior to the Effective Date
(collectively, “Confidential Information”). The Recipient shall not use the Disclosing Party’s
Confidential Information for any purpose except as permitted by this Agreement, or disclose
the same to anyone other than those of its Affiliates, directors, officers, employees, agents,
subcontractors, consultants or counsel as are necessary in connection with such Party’s
activities as provided in this Agreement or whose duties require access to such Confidential
Information. The Recipient shall obtain a written agreement from any directors, officers,
employees, agents, subcontractors, consultants and counsel prior to disclosure of the
Disclosing Party’s Confidential Information (unless such party is otherwise under a duty of
confidentiality to Recipient), to hold in confidence and not make use of such Confidential
Information for any purposes other than those permitted by this Agreement.

	10.2.	 	Exceptions to Confidentiality Obligations. The obligation of confidentiality
contained in this Agreement shall not apply to the extent that the Recipient can demonstrate
that (i) the disclosed information was at the time of such disclosure to the Recipient already
in the public domain other than as a result of actions or inactions of the Recipient, its
Affiliates or their respective, directors, officers, employees, agents, subcontractors,
consultants or counsel in violation hereof, (ii) the disclosed information subsequently enters
the public domain other than as a result of actions or inactions of the Recipient, its
Affiliates or their respective, directors, officers, employees, agents, subcontractors,
consultants or counsel in violation hereof, (iii) the disclosed information was rightfully
known by the Recipient or its Affiliates (as shown by its written records) prior to the date
of disclosure to the Recipient, (iv) the disclosed information was lawfully received by the
Recipient or its Affiliates on an unrestricted basis from a source unrelated to any Party to
this Agreement and not known by the Recipient to be under a duty of confidentiality to the
Disclosing Party, or (v) disclosure is required by a government regulatory agency as part of
such agency’s product license approval process, or is otherwise required by law, order or
regulation of a governmental agency or a court of competent jurisdiction, provided, however,
the Recipient shall not make any such disclosure without first notifying the Disclosing Party
and allowing the Disclosing Party a reasonable opportunity to seek injunctive relief from (or
a protective order with respect to) the obligation to make such disclosure.

17

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

11. INDEMNIFICATION

	11.1.	 	PPS’s Indemnification. Subject to the PPS’s limitation of liability, PPS shall
indemnify, defend and hold Javelin and its Affiliates, and their respective shareholders,
directors, officers, employees, agents, successors and assigns harmless from and against any
and all liability, loss, damages and expenses (including without limitation court costs and
reasonable attorneys’ fees) suffered as the result of claims, demands, costs or judgments made
or brought against Javelin to the extent such claims arise out of or are caused by PPS’s
negligence or misconduct in the Processing of Product.

	11.2.	 	Javelin’s Indemnification. Javelin shall indemnify, defend and hold PPS and its
Affiliates, and their respective shareholders, directors, officers, employees, agents,
successors and assigns harmless from and against any and all liability, loss, damages and
expenses (including without limitation court costs and reasonable attorneys’ fees) suffered as
the result of claims, demands, costs or judgments made or brought against PPS arising out of
or caused by (i) PPS’s Processing of the Product in accordance with Product Specifications,
including without limitation any claim that PPS’s Processing of the Product infringes or
misappropriates a third party’s patent, copyright, trade secret, trademark or other
proprietary right, (ii) any negligent act or omission of Javelin in connection with its
performance under this Agreement, (iii) the use of any Product supplied hereunder or of any
Javelin Component in humans, or (iv) the shipment, storage, or any other use of the Product
after delivery thereof to Javelin’s designated carrier, except in each case to the extent such
claims, demands, costs or judgments are caused by the misconduct or negligence of PPS or any
of its Affiliates, or their respective agents or employees.

	11.3.	 	Indemnification Procedure. The indemnifying Party shall have the right to control
any litigation and settlement discussions within the scope of the indemnities provided for in
this Article 11; provided, however, that the indemnifying Party shall not, without obtaining
the prior written consent of the indemnified Party, settle any litigation if such settlement
would impose an admission, obligation or liability on the indemnified Party. The indemnified
Party shall have the right to select and retain counsel, at the indemnified Party’s own
expense, to represent such Party in any litigation and settlement discussions. The indemnities
set forth in this Article 11 shall be inapplicable if the indemnifying Party is not notified
promptly of the claim for indemnification and is prejudiced by the delay in notice. All
indemnified Parties shall cooperate to the extent necessary in the defense of any claim within
the scope of the indemnities provided for in this Article 11. An indemnifying Party’s
assumption of the defense or disposition of any matter hereunder may be undertaken without
prejudice to its right to assert that it is not obligated to indemnify the indemnified Party
pursuant to the terms hereof.

18

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	11.4.	 	LIABILITY LIMITATION. PPS’S TOTAL AGGREGATE LIABILITY TO JAVELIN UNDER THIS
AGREEMENT SHALL NOT EXCEED [***] PER YEAR DURING EACH YEAR OF THE TERM. IN NO EVENT SHALL PPS
BE LIABLE FOR LOSS OF PROFITS, LOSS OF GOODWILL OR ANY PUNITIVE, EXEMPLARY, SPECIAL,
CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES OF ANY KIND, WHETHER IN CONTRACT, WARRANTY,
NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, AND REGARDLESS OF WHETHER PPS HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

	11.5.	 	Survival. The obligations of this Article 11 shall survive the expiration or
termination of this Agreement.

12. INSURANCE

	12.1.	 	(a) During the Term, and for a period of one year after the expiration of the final batch of
Product made under this Agreement, PPS shall obtain and maintain the following insurance:

	 	i	 	Commercial General Liability insurance, with limits (including
umbrella coverages) of not less than [***] per occurrence for bodily injury and
property damage liability and [***] in the aggregate. In addition, such
insurance shall include contractual liability and completed operations. Javelin
shall be named as an additional insured under this insurance, but only as
respects PPS’s obligations under this Agreement.
	 
	 	ii	 	Product Liability insurance with limits of not less than [***]
per occurance for bodily injury and property damage and [***] in the aggregate.
Javelin shall be names as an additional insured under this insurance, but only
as respects PPS’s obligations under this Agreement.
	 
	 	iii	 	Worker’s Compensation insurance as required under applicable
state law, and employer’s liability insurance with a limit of not less than
[***].
	 
	 	iv	 	Any insurance required under applicable US law.

	 	(b)	 	With respect to all insurance coverages under Section 12.1(a), and all
insurance carriers shall have a Best’s rating of A:XII or higher. All insurance
policies shall be occurrence form, except for Products Liability insurance, which is
under a claims made form. Notwithstanding the one-year period specified in Section

19

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	 	12.1(a), PPS shall carry Products Liability insurance for a minimum of five years
after the termination or expiration of this Agreement.
	 
	 	(c)	 	PPS shall furnish Javelin with certificates of insurance evidencing the above
requirements as soon as practicable after the Effective Date and each anniversary of
the Effective Date during the Term, and all policies will include provisions for at
least thirty (30) days’ written notice of any material change or cancellation.

	12.2.	 	(a) During the Term, for a period of one year after the expiration of the final batch of
Product made under this Agreement, Javelin shall obtain and maintain the following insurance:

	 	i	 	Commercial General Liability insurance, with limits (including
umbrella coverages) of not less than [***] combined single limit per occurrence
for bodily injury and property damage liability and [***] in the aggregate. In
addition, such insurance shall include contractual liability and completed
operations. PPS and Talecris Biotherapeutics Holdings Corp. shall be named as
an additional insured under this insurance, but only as respects Javelin’s
obligations under this Agreement.
	 
	 	ii	 	Product Liability insurance with limits of not less than [***]
per occurance for bodily injury and property damage and [***] in the aggregate.
PPS and Talecris Biotherapeutics Holdings Corp shall be named as additional
insured under this insurance but only as respects Javelin’s obligations under
this Agreement.
	 
	 	iii	 	Worker’s Compensation insurance as required under applicable
state law, and employer’s liability insurance with a limit of not less than
[***].
	 
	 	iv	 	Any insurance required under applicable US law.

	 	(b)	 	With respect to all insurance coverages under Section 12.2(a), all insurance
shall be primary or with a self-insured retention approved by Talecris Risk Management
in advance, and all insurance carriers shall have a Best’s rating of A:XII or higher.
All insurance policies shall be occurrence form, except for Products Liability
insurance, which is under a claims made form. Notwithstanding the one-year period
specified in Section 12.2(a), Javelin shall carry Products Liability insurance for a
minimum of five years after the termination or expiration of this Agreement.
	 
	 	(c)	 	Javelin shall furnish PPS with certificates of insurance evidencing the above
requirements as soon as practicable after the Effective Date and each anniversary

20

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 		 	of the Effective Date during the Term, and all policies will include provisions for
at least thirty (30) days’ written notice of any material change or cancellation.

13. DISPUTE RESOLUTION

	13.1.	 	Amicable Resolution. Prior to either Party filing any court action in connection
with any dispute, controversy or disagreement (each, a “Dispute”) arising between the Parties
in connection with this Agreement, the Parties shall attempt to resolve such Dispute amicably
in accordance with the terms of this Article 13. As requested by either Party upon the
occurrence of a Dispute, designated representatives of the Parties shall meet and attempt to
resolve such Dispute. If the Dispute is not resolved by the mutual agreement of such
designated representatives within fifteen (15) days after their first meeting to attempt to
resolve the Dispute, then the Dispute shall be referred to the respective senior management of
the Parties. If such senior managers have not resolved such Dispute within thirty (30) days
after the date that such Dispute was referred to them, then the Parties shall in good faith
consider binding arbitration after which they shall be free to pursue all remedies available
to them at law or in equity.

	13.2.	 	Arbitration. If referred to arbitration pursuant to paragraph 13.1 above, the
arbitration shall be administered by the American Arbitration Association before three (3)
arbitrators in accordance with its Commercial Arbitration Rules. Judgment on the award, if
any, rendered by the arbitrator may be entered in any court having appropriate jurisdiction.
The Arbitration shall be binding and shall take place in New York City at the offices of the
American Arbitration Association or at such other location as mutually agreed by the parties.

	13.3.	 	Provisional Remedies. Nothing in this Article 13 is intended or shall be deemed to
prevent either Party from seeking injunctive relief (or any other provisional remedy) from any
court having jurisdiction over the Parties and the subject matter of the dispute as necessary
to protect such Party’s name, confidential or proprietary information, trade secrets, or any
other proprietary rights. Nothing in this Article 13 is intended or shall be deemed to modify
the provisions of paragraph 3.5 (Javelin Testing) and the provisions of that paragraph 3.5
shall apply solely in all disputes falling thereunder.

14. RECALL

	14.1.	 	Costs and Expenses. Javelin shall immediately notify PPS in writing of any field
correction, injunction, stop sale order, governmental action or directive, or recall regarding
the Product. Javelin shall be solely responsible for implementing and carrying out any such
field correction, injunction, stop sale order, governmental action or

21

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	 	 	directive, or recall, and for complying with all applicable laws relating thereto. Any and
all costs and expenses resulting there from, including without limitation reasonable fees of
any experts or attorneys that may be used by either Party, shall be the responsibility of
Javelin; provided, however, that to the extent that such costs and expenses result at least
substantially from PPS’s breach of this Agreement, gross negligence or willful misconduct,
subject to PPS’s limitation of liability, PPS shall reimburse Javelin for the costs and
expenses proportionately attributable to such breach by PPS, including the costs of any
Product affected thereby and including the costs of any Javelin Components affected thereby.
	 
	14.2.	 	Survival. The obligations of this Article 14 shall survive the expiration or
termination
of this Agreement.

15. NOTICES AND MISCELLANEOUS TERMS

	15.1.	 	Notices. In any case where any notice or other communication is required or
permitted to be given under this Agreement, such notice or communication shall be in writing
and shall be deemed to have been duty given and delivered (a) if delivered in person, on the
date of such delivery, (b) if sent by confirmed facsimile transmission (with answer back
received), on the date of such facsimile transmission, or (c) if sent by overnight express or
registered or certified mail (with return receipt requested), on the date of receipt of such
mail, and shall be sent to the following address (or such other address as such Party may
designate from time to time in writing):

If to Javelin:

Javelin Pharmaceuticals, Inc.

1979 Marcus Avenue

Lake Success, NY 11042

Attention: Michael Moshman

                  VP, Clinical & Commercial Manufacturing

Facsimile:  212.554.4554

22

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

With a required copy to:

David Bernstein

General Counsel

Javelin Pharmaceuticals, Inc.

125 Cambridge Park Drive

Cambridge, MA 02140

Facsimile: 617.349.4505

If to PPS:

Precision Pharma Services, Inc.

155 Duryea Road

Melville, New York, 11747

Attention: Frank Sauers

                 Sr. Director, Operations

Facsimile: 631.752.7354

With a required copy to:

Randall A. Jones

VP and Deputy General Counsel

Talecris Biotherapeutics

79 TW Alexander Drive, Bldg. 4101

Research Triangle Park, North Carolina 27709

	15.2.	 	Force Majeure. Neither Party shall be deemed to be in breach of any of its
obligations under this Agreement or otherwise liable for any delay or failure to perform
hereunder if such delay or failure is due directly or indirectly, in whole or in part to a
strike, lock-out, work stoppage, boycott, or other labor disturbance, riot, insurrection,
revolution, flood, fire, earthquake or other natural disaster, casualty, accident, explosion,
equipment or machinery breakdown, sabotage, act or threat of war (whether declared or not),
act or threat of terrorism, fuel or power shortages, blockade, embargo, delay of carrier,
inability to obtain materials from sources of supply, change in law or regulation, injunction,
proclamation, order, requisition, mobilization, restraint, direction or other act or order of
government (whether or not now threatened), including without limitation an act or order of
the U.S. government under the Defense Production Act, 50 U.S.C. § 2061 et seq., or any other
cause beyond the reasonable control of such Party (each such cause an “Event of Force
Majeure”).

23

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	15.3.	 	Waiver. The failure of either Party to enforce at any time for any period any
provision of or any right deriving from this Agreement shall not be construed to be a waiver
of such provision or right or the right of such Party thereafter to enforce such provision or
right.

	15.4.	 	Headings. The headings contained in this Agreement do not form a substantive part of
this Agreement and shall not be construed to limit or otherwise modify its provisions.

	15.5.	 	Independent Contractors. The Parties are and shall remain at all times independent
contractors, and no agency, employment, or joint venture relationship exists between them or
between either Party and the employees of the other Party. Neither Party shall have, or shall
represent that it has, any power, right or authority to bind the other Party to any obligation
or liability, or to assume or create any obligation or liability on behalf of the other Party.

	15.6.	 	Binding Effect. This Agreement shall be binding upon and inure to the benefit of the
Parties and their respective successors and permitted assigns.

	15.7.	 	No Third Party Beneficiaries. The representations, warranties, covenants and
agreements set forth in this Agreement are for the sole benefit of the Parties and their
respective successors and permitted assigns, and nothing in this Agreement, express or
implied, is intended or shall be deemed to confer upon any other person or entity any legal or
equitable rights, benefits or remedies.

	15.8.	 	Enforceability. Should any part or provision of this Agreement be determined to be
unenforceable or in conflict with the laws of any jurisdiction, the validity or enforceability
of the remaining provisions shall not be affected by such determination, and the rights and
obligations of the Parties shall be construed and enforced as if the Agreement did not contain
the particular provision held to be unenforceable.

	15.9.	 	Entire Agreement. The terms and conditions herein contained together with the terms
and conditions of the documents attached as schedules hereto constitute the entire agreement
between the Parties relating to the subject matter of this Agreement and supersede all
previous oral and written agreements and other communications between the Parties with respect
to such subject matter, including without limitation any development agreements between the
Parties. No modifications of this Agreement shall be binding upon either Party unless approved
in writing by an authorized representative of each of the Parties. This paragraph 15.9
notwithstanding, the Quality Agreement shall be considered to be in full force and effect
during the Term of this Agreement, and any Renewal Term, and thereafter as may be appropriate.

24

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

	15.10.	 	Schedules and Exhibits. The schedules and exhibits attached to this Agreement and
the principles and conditions incorporated in such shall be deemed integral parts of this
Agreement and all references in this Agreement to this Agreement shall encompass such
schedules and exhibits and the principles and conditions incorporated therein. In the event of
a conflict between the terms and conditions set forth in Articles 1 through 15 of this
Agreement and the terms and conditions set forth in any schedule or exhibit to this Agreement,
the terms and conditions of Articles 1 through 15 shall control.

	15.11.	 	Counterparts. This Agreement may be executed by the Parties in counterparts, each
of which when so executed and delivered shall be considered to be an original, but all of
which shall together constitute but one and the same instrument.

	15.12.	 	Press Releases. The Parties agree to consult with each other before issuing any
press release or making any public statement with respect to this Agreement or the
transactions contemplated hereby and, except as may be required by applicable law or any
listing agreement with any national securities exchange or self-regulatory organization,
neither Party shall issue any such press release or make any such public statement without the
prior written approval of the other Party.

	15.13.	 	Choice of Law. This Agreement shall be construed and enforced according to the laws
of the State of New York, without regard to its choice of law rules or principles.

	15.14.	 	Quality. All matters dealing with the quality of Product shall be addressed in the
quality agreement attached hereto as Exhibit A (“Quality Agreement”). In the event that any
terms or conditions of the Quality Agreement are inconsistent with this Agreement, the terms
and conditions of this Agreement shall govern.

{Remainder of page intentionally left blank}

25

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their
respective duly authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	Javelin Pharmaceuticals, Inc.	 	 	 	Precision Pharma Services, Inc.	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Daniel B. Carr, M.D.
 

	 	 	 	By: 
	 	/s/ James A. Moose
 

	 	 
	Name:

	 	Daniel B. Carr, M.D.
	 	 	 	Name:
	 	James A. Moose	 	 
	Title:

	 	CEO & CMO
	 	 	 	Title:
	 	Vice President	 	 

 

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 1.15

[***]

 

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 1.3

[***]

 

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 6.1

[***]

 

 

[*CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH
PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK [***], HAS BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.]

SCHEDULE 6.7

[***]

30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]